CD63 Antikörper (Extracellular, Loop 2)

Produktnummer ABIN7581844

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch CD63 in FACS, WB, IHC und LCI. Es zeigt Reaktivität gegenüber Proben von Maus.

Kurzübersicht für CD63 Antikörper (Extracellular, Loop 2) (ABIN7581844)

Target: CD63

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CD63 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC), Live Cell Imaging (LCI)

Produktdetails anti-CD63 Antikörper

Bindungsspezifität: AA 177-190, Extracellular, Loop 2

Verwendungszweck: A Rabbit Polyclonal antibody to CD63 (extracellular)

Sequenz: CGNDFKESTI HTQG

Homologie: Rat - identical Won't recognize CD63 from human samples

Produktmerkmale: Anti-CD63 (extracellular) Antibody (ABIN7581844) is a highly specific antibody directed against an extracellular epitope of the mouse protein. The antibody can be used in western blot, immunohistochemistry and flow cytometry applications. It has been designed to recognize CD63 from mouse and rat samples. The antibody will not work with human samples.

Aufreinigung: Affinity purified on immobilized antigen.

Immunogen: CGNDFKESTIHTQG, corresponding to amino acid residues 177 - 190 of mouse CD63

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

WB: 1:200-1:500

FC: 5 μg per reaction

ICC: The optimal concentration should be determined by the user

IHC: 1:300

IP: The optimal concentration should be determined by the user

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: 25 μL, 50 μL or 0.2 mL double distilled water (DDW), depending on the sample size.

Konzentration: 0.8 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Details zu CD63

Target: CD63

Andere Bezeichnung: CD63

Hintergrund:

Synonyms: Tetraspanin-30, TSPAN30, Lysosomal-Associated Membrane Protein 3, LAMP-3, Granulophysin, Melanoma-Associated Antigen ME491

Description: CD63, also known as Tetraspanin-30 (Tspan-30), lysosomal-associated membrane protein 3 (LAMP-3), lysosome integral membrane protein 1 (Limp1), melanoma-associated antigen (ME491), and ocular melanoma-associated antigen (OMA81H), is a multi-transmembrane protein that plays a role in cancer malignancy.1CD63 is a highly N-glycosylated member of the transmembrane-4 superfamily of tetraspanin proteins. CD63 is composed of 238 amino acids comprising four transmembrane α-helices, two extracellular loops, and a short cytoplasmic tail. CD63 is located in late endosomes, lysosomes, secretory vesicles, and the plasma membrane. At the plasma membrane, CD63 interacts with cell adhesion molecules such as integrins in order to regulate intracellular signaling pathways for cell adhesion, motility, and survival. CD63 is also involved in membrane transport, fusion, and protein kinase signaling.1,2In addition to its role as a confirmed marker for cancer, the significance of CD63 in identifying exosomes has recently been highlighted. Exosomes are small extracellular vesicles, ranging from 50 to 150 nm in diameter, characterized by a lipid membrane structure. They are widely present in bodily fluids and can be generated by almost all cell types, whether in pathological or physiological conditions. Importantly, the contents of exosomes are carefully regulated by their originating cells, allowing them to convey specific information from the parent cells to other cells. This enables the assessment of the functional states of specific cells by examining the exosomes they release, paving the way for non-invasive cancer liquid biopsies facilitated by exosomes.1The presence of specific protein markers on exosomes has been observed, opening up possibilities for the development of an immunoaffinity-based strategy to separate exosomes. This strategy involves exploring the specific binding between these markers and their corresponding affinity agents, such as antibodies. The landscape of present-day biological research is undergoing a significant transformation due to the advancements in exosome-mediated therapeutics and diagnosis. Consequently, CD63 emerges as a highly promising target, not only for evaluating cancer, but also for delivering drugs with precision to tumor cells that express CD63. This targeted approach holds great potential for precise anti-cancer therapy.1

Gen-ID: 12512

UniProt: P41731